Healthcare in China Update: Priority Review for Foreign Rare Disease Drugs — Key Takeaways
Effective March 2025, China’s National Medical Products Administration (国家药品监督管理局, NMPA) expanded its priority review (优先审评, yōuxiān shěnpíng) pathway to include foreign-origin rare disease drugs that have been approved in at least two major regulatory jurisdictions. This policy change directly affects the estimated 20 million Chinese patients living with rare diseases (罕见病, hǎnjiàn bìng) — a patient pool larger than Australia’s entire population. For foreign executives, this update signals a tangible acceleration in market access: qualifying drugs can now expect a review timeline of 130 working days, versus the standard 200 working days, representing a 35% reduction in regulatory waiting time.
Why This Matters
China is the world’s second-largest pharmaceutical market, but its rare disease segment has long been underserved. Historically, foreign rare disease drugs faced multi-year approval backlogs, duplicate clinical trial requirements, and pricing uncertainty. The new priority review framework — outlined in the NMPA’s Announcement on Adjusting the Priority Review and Approval Procedure for Rare Disease Drugs (March 2025) — directly addresses these pain points. For foreign companies developing therapies for conditions like spinal muscular atrophy, Pompe disease, or hemophilia B, this update can reduce the time from global approval to China launch by 6 to 12 months. Moreover, the policy aligns with China’s national rare disease catalog, which now lists 207 rare diseases — up from 121 in the first edition (2018). Each listing increases the likelihood of special regulatory and reimbursement support.
Key Policy Highlights
The following table summarizes the most important changes under the updated priority review framework:
| Aspect | Previously | Updated (March 2025) | Impact for foreign firms |
|---|---|---|---|
| Eligibility for foreign drugs | Requires China-based clinical trial data | Can leverage data from US FDA, EMA, or PMDA approvals if approved in ≥2 jurisdictions | Reduces local trial costs by up to 60% for early-stage submissions |
| Priority review timeline | Average 200 working days (standard) | 130 working days (priority) — can be further expedited to 90 working days for “urgent unmet needs” | Speeds up market entry; aligns with US FDA Breakthrough Therapy median review time (~120 days) |
| Clinical data requirements | Full local Phase I–III data required | Acceptance of foreign data with a small bridging study (typically 20–40 patients) for most rare diseases | Lowers development cost by an estimated $10–15 million per drug |
| Orphan drug designation (孤儿药认定, gū’ér yào rèndìng) | Available only for domestic developers | Now open to foreign entities via a Hong Kong or Shanghai WFOE (外商独资企业, wàishāng dúzī qǐyè) structure | Expedited access to tax credits, fee waivers, and market exclusivity up to 7 years |
Five Critical Takeaways for Foreign Executives
- Accelerated timeline is real, but preparation is everything. The 130-day review period applies only to drugs that have already secured approval in at least two of the three major reference agencies (US FDA, European EMA, Japanese PMDA). If your drug is approved only in the US, you can still apply for priority review, but the NMPA may require a concurrent Phase II bridging trial — extending the timeline by 12–18 months. Action: Plan your global regulatory strategy to achieve dual-agency approval before submitting to China.
- Bridge study design must follow CDE guidance. The Center for Drug Evaluation (药品审评中心, CDE) released a companion document in April 2025 that specifies acceptable endpoints for rare disease bridging trials. For example, for enzyme replacement therapies, the CDE now accepts surrogate biomarkers (e.g., GAA activity levels) instead of clinical outcome measures in the bridging study. This mirrors the flexibility seen in the FDA’s accelerated approval pathway. However, the CDE expects at least 20% of these patients to be Chinese nationals — so a multi-center China-based arm is still mandatory in most cases.
- Reimbursement is not automatic. Priority review does not guarantee inclusion in the National Reimbursement Drug List (国家医保目录, NRDL). Only 34 rare disease drugs were included in the NRDL after the 2024 annual negotiation — a small fraction of the 207 listed rare diseases. Companies should begin health technology assessment (HTA) discussions with the National Healthcare Security Administration (NHSA) at least 18 months before expected priority approval. A modeled budget impact analysis based on the target patient population of 20 million is often required.
- Local partnerships can still derail timelines. Even with the eased regulatory pathway, the NMPA requires a local legal entity (e.g., a WFOE (外商独资企业, wàishāng dúzī qǐyè)) or a Chinese sponsor to hold the drug registration certificate. Many foreign companies choose to partner with a local clinical research organization (CRO) or establish a wholly foreign-owned enterprise (WFOE). Given that setting up a fully operational WFOE in Shanghai or Beijing takes an average of 4–6 months, foreign executives should initiate entity registration in parallel with global regulatory filings.
- Competitive intelligence is more critical than ever. The new priority review pathway is also available to domestic Chinese biotechs, many of which are developing biosimilar versions of rare disease drugs. As of May 2025, the NMPA had received 87 priority review applications for rare disease drugs — 52 from domestic companies and 35 from foreign firms. If your drug targets a rare disease with existing Chinese biosimilars in Phase III trials, the first-mover advantage window is narrow. For example, in the case of alglucosidase alfa for Pompe disease, the first biosimilar developer received priority review just 5 months after the innovator’s China approval.
Pitfalls to Navigate
1. Insufficient post-market surveillance data. The NMPA now requires a risk management plan (RMP) that includes a commitment to real-world data collection for Chinese patients. Failure to submit periodic safety update reports (every 6 months for the first 2 years, then annually) may result in revocation of priority review status. One foreign firm in 2024 lost its priority designation after missing the 6-month deadline — its drug reverted to standard review, delaying launch by 10 months.
2. Language and cultural gaps in dossiers. Even small translation errors in Chinese summaries can trigger requests for supplemental information (RFS), adding 30–60 days. In a 130-day review clock, a single RFS can erase the priority advantage. Best practice: Engage a specialized regulatory translation team with CDE submission experience, not just general translators. Budget at least 2–3 weeks for language quality assurance.
3. Pricing expectations vs. local affordability. China’s rare disease patient assistance programs often cap out-of-pocket costs at ~30% of annual income. If your drug’s wholesale price in the US exceeds $300,000/year, expect Chinese authorities to demand substantial volume discounts (40–60%) during NRDL negotiations. Plan for a net price ceiling of about $60,000–90,000 per year in China for most rare disease therapies.
Where to Go From Here
